Phase 2 N=93 A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 2.0; 3.1 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease
Chronic Lung Disease
Primary: Number of Unscheduled Face-to-face Physician Visits (Clinic Visits, ER Visits, and Hospitalizations) — 16; 21; 3; 5 visits — p=0.473
Phase 4 N=152 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism
Alcohol Dependence
Primary: Percent Heavy Drinking Days by mu Opioid Receptor Gene — 11.0; 18.0; 11.8; 18.7 percentage of days — p=0.724
Phase 2 N=56 Neurotropin Treatment of Fibromyalgia
Fibromyalgia
Primary: Fibromyalgia Impact Questionnaire — 49.9; 37.5; 39.9; 33.4 units on a scale
N/A N=50 One-Lung Ventilation in the Morbidly Obese Patient: Comparison of Double Lumen Versus Bronchial Blockers
Obesity
Primary: Time Taken for Endotracheal Tube Placement Procedure. — 3.4; 4.1 minutes
Phase 3 N=181 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.5; -4.2; -5.4 units on a scale
Phase 2 N=81 Photopheresis for the Treatment of Acute Graft Versus Host Disease
Graft Versus Host Disease
Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants
Phase 3 N=7,903 Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Primary: Annualised Rate of Moderate to Severe COPD Exacerbations During the Actual Treatment Period. — 0.97; 0.90 Rate per patient-year — p=0.0498
Phase 2 N=613 Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135…
N/A N=60 Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy
Endotracheal Intubation
Primary: Intubation Time — 60.2; 48.8; 58.6; 40.7 seconds
Phase 2 N=3 Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
N/A N=221 Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
Urinary Incontinence
Primary: Change of Stamey Grade From Baseline to 12 Months. — -1.17 units on a scale — p=<0.001
N/A N=20 Normal Tissue Oxygenation Following Radiotherapy
Radiation Toxicity
Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5
Phase 2 N=47 A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
Hepatocellular Carcinoma
Primary: Progression Free Survival (PFS) — 2.9 months
Phase 4 N=330 Valproate Versus Ketorolac Versus Metoclopramide
Acute Migraine
Primary: Headache Pain Level on a 0-10 Verbal Scale — 4.7; 3.9; 2.8 units on a scale